pharmaphorum media limited
Rosemount House
Rosemount Avenue
West Byfleet, Surrey
KT14 6LB
United Kingdom
For advertising queries please email advertising@pharmaphorum.com or for further information visit our Advertise page
For editorial queries please email editorial@pharmaphorum.com or for further information visit our Contribute page
For consulting queries please email consulting@pharmaphorum.com
 |
 |
 |
 |
 |
Karuna Therapeutics said this morning that the FDA has formally started its review of KarXT, aiming to become the first drug to reach the market for schizophrenia with a n
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
Patient centricity has been a key focus for pharma in 2023. However, extending beyond the merely discursive topic into sustained and tangible action at scale has been somewhat limited.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
It’s about that time of year when many global teams turn their attention towards annual strategic planning.
180+ Technical mRNA Specialists | 35+ Expert Speakers | 2 Content Streams
The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of
